SeekingAlpha · Sep 29, 2026
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
Cullinan Therapeutics' stock pullback may be a strong entry ahead of December 2026 autoimmune updates. Read more on CGEM here.
CG
NASDAQ · CGEM
Cullinan Therapeutics, Inc.
Healthcare · Medical - Pharmaceuticals
$16.25
Up+$0.21 (+1.31%)
Updated Oct 7, 2026, 3:44 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 730.18M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $11.68 – $23.19
- Volume
- 2.02M
- Avg. volume
- 1.2M
Price performance · CGEM
CGEM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CGEM closed at $16.25 after 21 trading sessions, down 25.08% for the selected period.
- Last close
- $16.25
- Period change
- -25.08%
- Period low
- $14.53
- Period high
- $21.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $17.24 | $17.70 | $16.06 | $16.25 | 2.02M |
| Oct 5, 2026 | $15.59 | $16.55 | $15.13 | $16.04 | 1.08M |
| Oct 2, 2026 | $14.76 | $15.56 | $14.59 | $15.51 | 1.16M |
| Oct 1, 2026 | $15.22 | $15.39 | $14.49 | $14.53 | 911.81K |
| Sep 30, 2026 | $15.39 | $15.78 | $14.955 | $15.35 | 1.07M |
| Sep 29, 2026 | $15.00 | $15.44 | $14.68 | $15.23 | 1.24M |
| Sep 28, 2026 | $14.71 | $15.185 | $14.20 | $14.95 | 1.11M |
| Sep 25, 2026 | $15.62 | $15.62 | $14.67 | $14.81 | 1.72M |
| Sep 24, 2026 | $16.60 | $16.875 | $14.7991 | $15.44 | 2.73M |
| Sep 23, 2026 | $21.67 | $21.67 | $16.78 | $16.87 | 2.6M |
| Sep 22, 2026 | $21.44 | $21.88 | $21.265 | $21.67 | 831.81K |
| Sep 21, 2026 | $21.45 | $21.785 | $20.98 | $21.35 | 763.87K |
| Sep 18, 2026 | $21.38 | $21.45 | $20.63 | $21.08 | 3.25M |
| Sep 17, 2026 | $21.06 | $21.58 | $20.805 | $21.36 | 756.84K |
| Sep 16, 2026 | $20.50 | $20.84 | $20.195 | $20.63 | 825.81K |
| Sep 15, 2026 | $20.38 | $20.705 | $19.64 | $20.54 | 1.06M |
| Sep 14, 2026 | $18.55 | $20.93 | $18.51 | $20.40 | 1.42M |
| Sep 11, 2026 | $21.16 | $21.34 | $20.10 | $20.59 | 1.09M |
| Sep 10, 2026 | $20.99 | $21.215 | $20.495 | $21.00 | 805.67K |
| Sep 9, 2026 | $21.30 | $21.795 | $21.08 | $21.31 | 1.28M |
| Sep 8, 2026 | $21.61 | $22.4101 | $21.28 | $21.69 | 953.74K |
Latest CGEM news
The latest Smart Investors Daily articles mentioning CGEM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CGEM research
Overview
Company profile and research snapshot.
Company profile
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $32.67
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 25, 2026 | BTIG | Buy | — |
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. President and CEO Nad
Yahoo · Sep 26, 2026
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...
Benzinga · Sep 25, 2026
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
